Two novel GPER agonists induce gene expression changes and growth effects in cancer cells

Current Cancer Drug Targets

Volumn 12, Issue 5, 2012, Pages 531-542

  Lappano, R ^a   Rosano, C ^b   Santolla, M F ^a   Pupo, M ^a   de Francesco, E M ^a   de Marco, P ^a   Ponassi, M ^b   Spallarossa, A ^c   Ranise, A ^c   Maggiolini, M ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer cells; Endometrial cancer cells; Estrogen receptors; GPER L1; GPER L2; GPR30 GPER

Indexed keywords

1 [BIS(PHENYLTHIO)METHYL]IMIDAZOLIDINE 2 THIONE; 7 [[[2 (DIETHYLAMINO)ETHYL]AMINO]METHYL] 5 IMINO 1,3,6 TRIPHENYL 5,6 DIHYDROPYRIMIDO[4,5 D]PYRIMIDINE 2,4(1H,3H) DITHIONE; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GPER L1 PROTEIN; GPER L2 PROTEIN; HORMONE RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; CHEMICAL STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENDOMETRIUM CANCER; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC TRANSFECTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 84861737062     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800673284     Document Type: Article

References (44)

1. Lappano, R.; Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 2011, 10, 47-60.
2. Maggiolini, M.; Picard, D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J. Endocrinol. 2010, 204, 105-14.
3. Albanito, L.; Madeo, A.; Lappano, R.; Vivacqua, A.; Rago, V.; Carpino, A.; Oprea, T. I.; Prossnitz, E. R.; Musti, A. M.; Andò, S.; Maggiolini, M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007, 67, 1859-66.
4. Albanito, L.; Lappano, R.; Madeo, A.; Chimento, A.; Prossnitz, E. R.; Cappello, A. R.; Dolce, V.; Abonante, S.; Pezzi, V.; Maggiolini, M. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect. 2008, 116, 1648-55.
5. Sirianni, R.; Chimento, A.; Ruggiero, C.; De Luca, A.; Lappano, R.; Andò, S.; Maggiolini, M.; Pezzi, V. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 1βestradiol on mouse spermatogonial GC-1 cell line. Endocrinology 2008, 149, 5043-5051.
6. Vivacqua, A.; Lappano, R.; De Marco, P.; Sisci, D.; Aquila, S.; De Amicis, F.; Fuqua, S. A.; Andò, S.; Maggiolini, M. G proteincoupled receptor 30 expression is upregulated by EGF and TGFalpha in estrogen receptor alpha-positive cancer cells. Mol. Endocrinol. 2009, 11, 1815-1826.
7. Prossnitz, E. R.; Maggiolini, M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell Endocrinol. 2009, 308, 32-38.
8. Prossnitz, E. R; Barton, M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 2011, 7, 715-26.
9. Maggiolini, M.; Vivacqua, A.; Fasanella, G.; Recchia, A. G.; Sisci, D.; Pezzi, V.; Montanaro, D.; Musti, A. M.; Picard, D.; Andò, S. The G protein coupled receptor GPR30 mediates c-fos upregulation by 17β-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 2004, 279, 27008-27016.
10. Pandey, D. P.; Lappano, R.; Albanito, L.; Madeo, A.; Maggiolini, M.; Picard, D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009, 28, 523-532.
11. Vivacqua, A.; Bonofiglio, D.; Albanito, L.; Madeo, A.; Rago, V.; Carpino, A.; Musti, A. M.; Picard, D.; Andò, S.; Maggiolini, M. 17β-Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupledreceptor GPR30. Mol. Pharmacol. 2006, 70, 1414-1423.
12. Vivacqua, A.; Bonofiglio, D.; Recchia, A. G.; Musti, A. M.; Picard, D.; Andò, S.; Maggiolini, M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol. 2006, 20, 631-646.
13. Albanito, L.; Sisci, D.; Aquila, S.; Brunelli, E.; Vivacqua, A.; Madeo, A.; Lappano, R.; Pandey, D. P.; Picard, D.; Mauro, L.; Andò, S.; Maggiolini, M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptornegative breast cancer cells. Endocrinology 2008, 149, 3799-808.
14. Smith, H. O.; Leslie, K. K.; Singh, M.; Qualls, C. R.; Revankar, C. M.; Joste, N. E.; Prossnitz, E. R. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 2007, 196, 386. e1-386. e11.
15. Smith, H. O.; Arias-Pulido, H.; Kuo, D. Y.; Howard, T.; Qualls, C. R.; Lee, S. J.; Verschraegen, C. F.; Hathaway, H. J.; Joste, N. E.; Prossnitz, E. R. GPR30 predicts poor survival for ovarian cancer. Gynecol. Oncol. 2009, 114, 465-471.
16. Filardo, E. J.; Graeber, C. T.; Quinn, J. A.; Resnick, M. B.; Giri, D.; DeLellis, R. A.; Steinhoff, M. M.; Sabo, E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 2006, 12, 6359-6366.
17. Filardo, E. J.; Quinn, J. A.; Bland, K. I.; Frackelton, A. R. Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14, 1649-1660.
18. Filardo, E. J.; Quinn, J. A.; Frackelton, A. R. Jr.; Bland, K. I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 2002, 16, 70-84.
19. Thomas, P.; Pang, Y.; Filardo, E. J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146, 624-632.
20. Lappano, R.; Rosano, C.; De Marco, P.; De Francesco, E. M.; Pezzi, V.; Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell Endocrinol. 2010, 320, 162-170.
21. Bologa, C. G.; Revankar, C. M.; Young, S. M.; Edwards, B. S.; Arterburn, J. B.; Kiselyov, A. S.; Parker, M. A.; Tkachenko, S. E.; Savchuck, N. P.; Sklar, L. A.; Oprea, T. I.; Prossnitz, E. R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2006, 2, 207-212.
22. Dennis, M. K.; Burai, R.; Ramesh, C.; Petrie, W. K.; Alcon, S. N.; Nayak, T. K.; Bologa, C. G.; Leitao, A.; Brailoiu, E.; Deliu, E.; Dun, N. J.; Sklar, L. A.; Hathaway, H. J.; Arterburn, J. B.; Oprea, T. I.; Prossnitz, E. R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5, 421-427.
23. Ramesh, C.; Nayak, T. K.; Burai, R.; Dennis, M. K.; Hathaway, H. J.; Sklar, L. A.; Prossnitz, E. R.; Arterburn, J. B. Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J. Med. Chem. 2010, 53, 1004-1014.
24. Lappano, R.; Santolla, M. F.; Pupo, M., Sinicropi, M. S.; Caruso, A.; Rosano, C.; Maggiolini, M. MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells. Breast Cancer Res. 2012, 14, R12.
25. Ranise, A.; Spallarossa, A.; Schenone, S.; Bruno, O.; Bondavalli, F.; Pani, A.; Marongiu, M. E.; Mascia, V.; La Colla, P.; Loddo, R. Synthesis and antiproliferative activity of basic thioanalogues of merbarone. Bioorg. Med. Chem. 2003, 11, 2575-2589.
26. Ranise, A.; Cesarini, S.; Spallarossa, A.; Sancassan, F.; Bondavalli, F.; Bruno, O.; Schenone, S.; Menozzi, G.; Fossa, P.; Mosti, L. Unprecedented one-pot stereoselective synthesis of Knoevenageltype derivatives via in situ condensation of N-methyleniminium salts of ethylenethiourea and ethyleneurea with active methylene reagents. Synthesis 2007, 16, 2495-2502.
27. Bunone, G.; Briand, P. A.; Miksicek, R. J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
28. Webb, P.; Nguyen, P.; Shinsako, J.; Anderson, C.; Feng, W.; Nguyen, M. P.; Chen, D.; Huang, S. M.; Subramanian, S.; McKinerney, E.; Katzenellenbogen, B. S.; Stallcup, M. R.; Kushner, P. J. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 1998, 12, 1605-1618.
29. Maggiolini, M.; Bonofiglio, D.; Marsico, S.; Panno, M. L.; Cenni, B.; Picard, D.; Andò, S. Estrogen receptors a mediates the proliferative but not the cytotoxic dose dependent effects of two major phytoestrogens on human breast cancer cells. Mol. Pharmacology 2001, 60, 595-602.
30. Lappano, R.; Rosano, C.; Madeo, A.; Albanito, L.; Plastina, P.; Gabriele, B.; Forti, L.; Stivala, L. A.; Iacopetta, D.; Dolce, V.; Andò, S.; Pezzi, V.; Maggiolini, M. Structure activity relationships of resveratrol and derivatives in breast cancer cells. Molecular Nutrition and Food Research 2009, 53, 845-858.
31. Madeo, A.; Vinciguerra, M.; Lappano, R.; Galgani, M.; Gasperi-Campani, A.; Maggiolini, M.; Musti, A. M. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 2010, 29, 978-91.
32. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2A crystal structure. J. Mol. Biol. 2004, 342, 571-583.
33. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779-815.
34. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D: Biol. Crystallogr. 1997, 53, 240-255.
35. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Docking of flexible ligands: Applications of AutoDock. J. Mol. Recognition 1996, 9, 1-5.
36. Sanner, M. F.; Duncan, B. S.; Carillo, C. J.; Olson, A. J. Integrating computation and visualization for biomolecular analysis: an example using Python and AVS Packages. Symp. Biocomput. 1999, 401-412.
37. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-12.
38. Curran, T.; Franza, B. R. J. Fos and Jun: the AP1 connection. Cell 1988, 55, 395-397.
39. Milde-Langosch, K. The Fos family of transcription factors and their role in tumourigenesis. European Journal of Cancer 2005, 41, 2449-2461.
40. Madeo, A.; Maggiolini, M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res. 2010, 70, 6036-46.
41. Ignatov, T.; Eggemann, H.; Semczuk, A.; Smith, B.; Bischoff, J.; Roessner, A.; Costa, S. D.; Kalinski, T.; Ignatov, A. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am. J. Obstet. Gynecol. 2010, 203, 595. e9-16.
42. Ignatov, A.; Ignatov, T.; Roessner, A.; Costa, S. D.; Kalinski, T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res. Treat. 2010, 123, 87-96.
43. Thomas, P.; Dong, J. Binding and activation of the seventransmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol. 2006, 102, 175-9.
44. Prossnitz, E. R.; Barton, M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat. 2009, 89, 89-97.